Poster 1
Efficacy and Safety of Baricitinib in Moderate to Severe Atopic Dermatitis: Results of Two Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-week Trials (BREEZE-AD1 and BREEZE-AD2.
Poster 2
Rapid and Concurrent Improvements in Signs and Symptoms of Atopic Dermatitis with Baricitinib in Phase 3 Studies.
View the poster more closely.
Poster 3
A Belgian Consensus On The Definition Of A Treat-To-Target Outcome Set In Psoriasis Management.
View the poster more closely
Poster 4
Novel mutation in the ichthyin gene erroneously diagnosed and treated as ‘Ichthyosis vulgaris’ and ‘Psoriasis’.
View the poster more closely.
Poster 5
The many faces of granulomatous facial eruptions: a case report of granulomatous acne rosacea.
View the poster more closely.
Poster 6
Secondary resistance to Vismodegib through acquired pathogenic SMO mutations: a case series.
View the poster more closely.
Poster 7
Skin parameter maps in multispectral dermoscopy.
Listen to the author.
View the poster more closely.
Poster 8
Utility of patch testing for the diagnosis of delayed-type hypersensitivity reactions to clindamycin.
View the poster more closely.
Poster 9
Diagnostic approach to harlequin syndrome: a case report.
Listen to the author.
View the poster more closely.
Poster 10
Myth, belief and dogmatic thinking moves into hair science and technology during our XXIst century.
View the poster more closely
Poster 11
Secukinumab sustainability: The Belgian Experience.
View the poster more closely.
Poster 12
Acral pigmented lesions: do dermoscopy!
Listen to the author
View the poster more closely.
Poster 13
Inspect the skin, but don’t forget the brain: a case of Giant Congenital Melanocytic Nevus in a newborn.
View the poster more closely.
Poster 14
Optimizing skin cancer detection in the general population: an early access lesion-directed consultation.
View the poster more closely
Poster 15
Nailfold videocapillaroscopy: a diagnostic tool when clinical evaluation is misleading.
View the poster more closely.
Poster 16
Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis.
Poster 17
A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 12-Week Efficacy, Safety, and Speed of Response from a Randomized, Double-Blinded Trial.
Poster 18
A unique collection of books focussing on hair and skin at the "Fonds Van Neste".
View the poster more closely
Verder lezen?
Word nu lid van de Koninklijke Belgische Vereniging voor Dermatologie en Venerologie (KBVDV) en de Beroepsvereniging der Belgische Dermatologen en Venerologen (BBDV)!
Als lid van deze verenigingen geniet je tal van voordelen, waaronder toegang tot alle content van onze website en
de website van de Beroepsvereniging. Daarnaast betaal je een sterk verlaagd voordeeltarief voor de jaarlijkse Belgian Dermatology days én ontvang je regelmatig newsletters met relevante informatie over de uitoefening van ons beroep. Bovendien krijg je ook een korting op de website van contactallergie (met oa. allergenenlijsten) en een polis burgerlijke aansprakelijkheid beroep, speciaal ontwikkeld voor onze discipline, aan zeer gunstige voorwaarden.